Insmed Incorporated (INSM) is up 16.1% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely catalyst was a report that Sanofi is evaluating a potential acquisition of Insmed, which would naturally push shares higher on takeover expectations. The move was likely amplified by Insmed’s already strong commercial momentum, including rapid BRINSUPRI growth, higher 2026 product guidance, and continuing pipeline progress.
Details:
Sources:
Bloomberg, Insmed, Reuters
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$INSM Insider Trading Activity
$INSM insiders have traded $INSM stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:
- ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 2 sales selling 242,220 shares for an estimated $32,207,189.
- MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 6 sales selling 43,899 shares for an estimated $5,303,018.
- WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 7 sales selling 35,519 shares for an estimated $3,781,343.
- DAVID R BRENNAN sold 25,000 shares for an estimated $3,100,000
- MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 3 sales selling 10,114 shares for an estimated $1,060,833.
- MELVIN MD SHAROKY sold 5,000 shares for an estimated $637,650
- SARA BONSTEIN (Chief Financial Officer) sold 2,404 shares for an estimated $245,857
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$INSM Hedge Fund Activity
We have seen 400 institutional investors add shares of $INSM stock to their portfolio, and 411 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 32,194,934 shares (-99.1%) from their portfolio in Q3 2026, for an estimated $3,674,729,766
- DARWIN GLOBAL MANAGEMENT, LTD. removed 6,431,163 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $734,052,944
- AQR CAPITAL MANAGEMENT LLC added 4,600,702 shares (+750.7%) to their portfolio in Q3 2026, for an estimated $525,124,126
- VESTAL POINT CAPITAL, LP added 2,475,000 shares (+990.0%) to their portfolio in Q3 2026, for an estimated $282,496,500
- JPMORGAN CHASE & CO removed 2,184,633 shares (-20.9%) from their portfolio in Q3 2026, for an estimated $249,354,010
- CITADEL ADVISORS LLC removed 1,836,285 shares (-71.8%) from their portfolio in Q3 2026, for an estimated $209,593,569
- RTW INVESTMENTS, LP removed 1,746,335 shares (-36.1%) from their portfolio in Q3 2026, for an estimated $199,326,676
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$INSM Congressional Stock Trading
Members of Congress have traded $INSM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $INSM stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 06/10.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$INSM Analyst Ratings
Wall Street analysts have issued reports on $INSM in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/04/2026
- Guggenheim issued a "Buy" rating on 11/02/2026
- Morgan Stanley issued a "Overweight" rating on 10/21/2026
- Barclays issued a "Overweight" rating on 09/30/2026
- Goldman Sachs issued a "Buy" rating on 09/24/2026
- Roth Capital issued a "Buy" rating on 09/15/2026
- JP Morgan issued a "Overweight" rating on 08/10/2026
To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.
$INSM Price Targets
Multiple analysts have issued price targets for $INSM recently. We have seen 13 analysts offer price targets for $INSM in the last 6 months, with a median target of $195.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $220.0 on 11/04/2026
- Vamil Divan from Guggenheim set a target price of $201.0 on 11/02/2026
- Matthew Harrison from Morgan Stanley set a target price of $213.0 on 10/21/2026
- Eliana Merle from Barclays set a target price of $207.0 on 09/30/2026
- Andrea Newkirk from Goldman Sachs set a target price of $188.0 on 09/24/2026
- Adam Walsh from Roth Capital set a target price of $198.0 on 09/15/2026
- Jessica Fye from JP Morgan set a target price of $175.0 on 08/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.